On Demand: Providing Better Patient Care
June 2-4 2026, Las Vegas Nevada
“The objectives were clear and relevant. The session provided a good understanding of the relationship between their risk factors, potential complications, and the importance of lifestyle modifications and proper management. I feel the objectives were successfully met.”
“Objectives were met and included information that I can absolutely apply in practice. I work in a clinic with a weight loss program, so the more expertise I have in this area, the more valuable I can be to the patients and the care team as a whole. Dr. Bland is an excellent speaker! He presents the material in an engaging and digestible way, encourages participation, and offers insights from his own practice as well. The jeopardy knowledge check at the end was great! Thanks ULS!
clearly stated, was interesting way to achieving the objectives.”
About This Course
This course provides 15 contact hours of pharmacy CE and (1.5 CEU) of live AAFP/ AMA PRA Category 1 Credit™, ACPE and pharmacology CE/CME credit.
Price $250
Recorded Live on June 2-4 2026 in Las Vegas Nevada
Term of Approval is from 06/02/2026 to 06/02/2027
-
Apply recommendations from the American College of Cardiology/American Heart Association guidelines for treatment of patients with hypertension and dyslipidemia
Review lifestyle modifications that are recommended for the treatment and prevention of cardiovascular disease
Summarize how future cardiovascular risk is estimated in primary prevention patients using the Pooled Cohort Equations and PREVENT calculator.
Apply the treatment approaches recommended in the most recent ACC-AHA hypertension and dyslipidemia guidelines
llustrate emerging pharmacotherapies for the treatment of hypertension and dyslipidemia
Interpret the evidence and role in therapy of nonstatin medications in the treatment of hypercholesterolemia.
Create treatment plans that reduce the risk of cardiovascular disease
-
Overcoming Obesity: Update on Current and Future Pharmacotherapy Options
1. Describe appropriate patients who may benefit from obesity pharmacotherapy.
2. Evaluate common obesity medications with potential therapeutic uses as well as common and severe adverse reactions.
3. Identify potential future obesity medication therapies that may offer advantages over current FDA-approved agents.
Drug Interactions:
4. Identify common drug interaction mechanisms including cytochrome P450 enzymes.
5. Identify relevant clinical drug interactions for common medications.
6. Delineate assessment and management strategies for common interactions.
Obesity and Drug Interactions Jeopardy
7: Identify key laboratory values and parameters for monitoring drug therapy.
8. Describe key characteristics of common drug therapies.
9 Identify clinical pearls from various pharmacotherapy therapies.
-
New Drug Update:
1. Describe new drugs approved in the last 12-18 months that have potential to impact clinical practice.
2. Discuss clinical and practical pearls of each new agent where applicable compared to standard therapies.
3. Evaluate each agent's efficacy and safety data to best determine role in therapy.
Review of Current Osteoporosis Treatments:
4. Differentiate pharmacotherapy options for the management of osteoporosis.
5. Apply current osteoporosis treatment guidelines to develop individualized treatment plans.
6. Identify strategies to optimize long-term clinical and safety outcomes.
New Drug, Osteoporosis Jeopardy
7: Identify key laboratory values and parameters for monitoring drug therapy.
8. Describe key characteristics of common drug therapies.
9 Identify clinical pearls from various pharmacotherapy therapies.
Dr. Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS, BCACP
Associate Dean for Clinical Affairs, Ambulatory Care Pharmacy, Cardiovascular Risk Reduction Department of Clinical Pharmacy Secondary Appointment - Department of Family Medicine, School of Medicine
Dr. Christopher M. Bland | Pharm.D., FCCP
Clinical and Administrative Pharmacy, SavannahAlbert W. Jowdy Professor in Pharmacy CareCo-founder of Southeastern Research Group Endeavor (SERGE45) and TeachMePharm
More …
Accreditation Information - Category 1
PHARMACISTS:
University Learning Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. These programs are accredited for all pharmacists.
University Learning Systems is approved by CE Broker, Tracking #50-11357 and reports to the Florida Board of Pharmacy.
CONSULTANT PHARMACISTS: Some consultant pharmacist boards accept University Learning Systems courses for recertification either as is or with board approval. Please contact your board regarding course approval and ULS with any questions.
CANADIAN PHARMACISTS:Canadian Council on Continuing Education in Pharmacy (CCCEP) accepts courses accredited by the Accreditation Council for Pharmacy Education (ACPE).
NURSE PRACTITIONERS
American Nurses Credentialing Center (ANCC)and National Certification Corporation (NCC) accepts ACPE and AAFP credit. University Learning Systems courses fulfill the pharmacology requirements for ANCC Continuing Education Hours for certification renewal.
American Association of Nurse Practitioners (AANP) accepts AAFP/ AMA PRA Category 1™ to fulfill the pharmacology requirements for AANP Continuing Education Hours for certification renewal.
NURSES
University Learning Systems is approved by the California Board of Registered Nursing, Provider Number CEP 11409, and CE Broker Tracking #50-11357:
CE Broker is approved by these Boards of Nursing: Arkansas, Florida, District of Columbia, Georgia, Kentucky, New Mexico, North Dakota, South Carolina, West Virginia.The same hours submitted to renew NP certification may be submitted to a State Board of Nursing for re-licensure.
PHYSICIANS/ PHYSICIAN ASSISTANTS:
The AAFP has reviewed Providing Better Patient Care 2026 - Enduring and deemed it acceptable for up to 15.00 Enduring Materials, Self-Study AAFP Prescribed credit(s). Term of Approval is from 06/02/2026 to 06/02/2027. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
CME programs approved by the AAFP are eligible for through the American Osteopathic Association (AOA).
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for Prescribed credit from AAFP. Physician assistants may report the number of hours stated above of Category I credit for completing this program.
University Learning Systems is approved by CE Broker, Tracking #50-11357 and reports to the Florida Board of Medicine.
CANADIAN PHYSICIANS: Members of the College of Family Physicians of Canada are eligible to receive up to 15 MAINPRO-M1 credits for participation in this activity due to reciprocal agreement with the American Academy of Family Physicians.
OTHER HEALTH PROFESSIONALS: Please contact your respective board regarding approval.